Combivir is an anti-HIV drug of the category Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Marketed by Glaxo SmithKline, Combivir was approved by the U.S. Food and Drug Administration (FDA) for use by those people who are living with HIV in the year 1997.
Combivir is a combination of two drugs, 300 mg of Retrovir and 150 mg of Epivir. It prevents HIV from altering the genetic material of healthy T-cells. This, in turns, prevents the cells from producing new virus and decreases the amount of virus in the body. Combivir must be combined with at least one other anti-HIV medicine, usually with a Protease Inhibitor (PI) or with a Non-nucleaside Reverse Transcriptase Inhibitor (NNRTI).
Combivir is a tablet that is taken twice a day, one tablet in the morning and one in the evening. It can be taken with or without food. It is the same effective as in the case of Retrovir and Epivir taken as separate pills together. Combivir is listed as a preferred NRTI option that is used in combination with either a PI or a NNRTI, in the treatment guidelines of United States Department of Health and Human Services.
Combivir, the drug for the HIV Patients, may have some side effects also. Taking Combivir can lead to the Bone Marrow problems as the one of its two active drugs, Retrovir, cause some problems such as decreased production of red blood cells and/or white blood cells. If you develop unusual fatigue, pale skin, sore throat, fever, or chills, which may be the signs of bone marrow problems, it is strongly advisable to contact your physician immediately. The presence of Retrovir in Combivir may also cause myopathy, which damages the muscles including heart. The other common symptoms that can be noticed nausea, vomiting pain in upper stomach, feeling sick or tired, yellowing of the skin or eyes. All of these should immediately be reported to the physician.
For more information on HIV/AIDS Drugs, please go through the website sitagita.
Did you like Krissh 3's theatrical trailer?
|Yes||57% | 89 votes|
|No||31% | 48 votes|
|Obviously||11% | 17 votes|
|Total Votes: 154|
|View all Polls|